Participated · Series B · May 2021

HiberCell develops therapeutic molecules aimed at preventing cancer relapse and metastasis by targeting stress biology and innate immunity. The company’s lead candidate, HC-5404-FU, is the first from its 'stress modulator' platform and reportedly has direct anti-tumor activity while reprogramming the immunosuppressive tumor microenvironment. HiberCell views cancer as a chronic disease and is focused on therapies that address relapse and metastasis. The company will use proceeds from its recent financings to support clinical development of these novel therapeutics. HiberCell is led by Co-Founder and CEO Alan Rigby, Ph.D. and is based in New York City. HiberCell develops therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers to prevent relapse and metastasis. The company is exclusively focused on DTC-directed drug discovery and development. At launch, Alan Rigby, Ph.D., will serve as president and chief scientific officer; Ari Nowacek, Ph.D., M.D., will serve as vice president of operations and business development; and Mark Mulvihill, Ph.D., will serve as vice president of chemistry and drug discovery. Its team comprises cancer scientists, venture capitalists and drug developers. HiberCell raised $60.75M in Series A financing to advance its therapeutic programs. The company has assembled a board and a scientific advisory board with academic and industry leaders to guide its programs.

Participated · Series B · May 2018

Cortexyme is a clinical-stage pharmaceutical company based in South San Francisco developing therapeutics to alter the course of Alzheimer’s and other degenerative diseases. Its lead small molecule, COR388, is a first-in-class, orally administered bacterial protease inhibitor that targets a pathogen Cortexyme discovered in the brains of Alzheimer’s patients. COR388 completed placebo-controlled single ascending dose and multiple ascending dose trials in healthy volunteers and was reported to be safe, well tolerated, and to show a favorable pharmacokinetic profile and tissue distribution. The company plans to start a phase 2 proof-of-efficacy study in Alzheimer’s patients next year. Additional proprietary small molecules are advancing in preclinical development. Financially, Cortexyme completed a $76 million Series B financing with participation from both new and existing investors. Cortexyme is developing therapeutics and diagnostics intended to alter the course of Alzheimer’s disease and other degenerative disorders. The company is targeting a specific, undisclosed pathogen tied to neurodegeneration and is testing several patent-pending lead therapeutics in preclinical studies. It intends to use new funding to advance ongoing development of these novel therapeutics and diagnostics. The company is led by CEO Casey Lynch and is based in South San Francisco, California. Prior to this round, Cortexyme had raised $1.025M, including an investment award from Breakout Labs. Cortexyme is a San Francisco-based healthcare technology company developing novel therapeutics and diagnostics for Alzheimer’s disease and other neurodegenerative disorders. The company is led by CEO Casey Lynch and is advancing preclinical-stage programs. Cortexyme raised $1M in funding. The round was led by evergreen fund Dolby Family Ventures, which invested $500K. The company intends to use the funds to continue preclinical research and advance its therapeutic and diagnostic programs. Cortexyme is developing therapeutics intended to alter the course of Alzheimer’s disease and other disorders of aging. Its scientific breakthrough is based on a link between a specific pathogen and human brain degeneration discovered by founder Stephen Dominy, M.D. The company plans to develop a diagnostic and treatment-monitoring method for the general population, test several patent-pending therapeutics, and develop novel small-molecule candidates. Breakout Labs announced funding to allow Cortexyme to pursue those development activities. Breakout Labs is Peter Thiel’s nonprofit fund that provides up to $350,000 to companies to achieve specific milestones. Cortexyme is based in San Francisco and is led by CEO Casey Lynch.

Participated · Series A · Oct 2017

Impossible Objects develops composite-based additive manufacturing (CBAM) technology that combines high-performance polymers such as Nylon and PEEK with long-fiber carbon and fiberglass sheets to produce complex parts at production speeds and volumes. The company sells printers (including its Model One and CBAM-2) and engineered materials for additive and composites manufacturing markets. It has partnered with BASF to enable its printers to support BASF’s Ultrasint PA6 powder for high-performance carbon fiber–PA6 composite parts. Led by Founder and Chairman Bob Swartz, the company is focused on expanding operations and broadening its business reach. The article notes a recent funding infusion that will be used to continue that expansion. No operating metrics (revenue or user counts) were disclosed in the article. Impossible Objects develops a 3D printing process that leverages high-speed 2D graphics technologies to produce composite parts combining materials like carbon fiber, Kevlar, fiberglass and high-performance polymers such as PEEK. The company’s Model One printer was introduced in 2017 as a pilot system, with pilot units available on a selective basis and commercial availability planned for 2018. Impossible Objects acquired its first customer, Jabil Inc., during the Model One pilot phase. The business intends to use recent funding to accelerate technology development and roll out of its systems. Financially, the company has raised more than $9m to date, including the latest institutional round. Leadership is headed by founder and chairman Robert Swartz and CEO Larry Kaplan.

Led · Equity · Dec 2015

Eved is a Chicago, IL-based event commerce company that provides a collaborative procurement platform and marketplace for events. Its platform integrates with existing systems to streamline payment, enforce compliance, and capture event spend data. The company is led by Talia Mashiach, CEO, Founder & Product Architect, and serves clients and partners including Dell, Eli Lilly and Company, and BCD Meetings & Events. In December 2015 Eved raised $14.3m to accelerate sales, support its clients and partners, and increase hiring. The round was led by Huizenga Capital Management with participation from MK Capital, Pritzker Group Venture Capital and Merrick Ventures. In conjunction with the funding, Sean Chou (former CTO for Fieldglass) and David Bradley (The Huizenga family) joined Eved’s Board of Directors. Founded in 2010 and based in Chicago, Eved operates an online marketplace for the meeting and events industry. Its proprietary platform offers sourcing, marketing and e-commerce tools that let buyers find suppliers, send and track RFPs, and manage supplier networks. Suppliers can use Eved to expand their businesses online, meet buyer demand for lower pricing, and maintain margins; companies can also buy directly from suppliers and track purchases via e-invoices. The company targets the $263 billion meeting and event industry and now has over 2,500 users across organizations, third-party meeting and incentive companies, event planners, destination management companies, hotels, venues and suppliers. Partners say the platform reduces manual labor and can lower costs—New World Ventures' Matt McCall estimates savings of as much as 25%. Eved plans to use new funding to scale and expand its proprietary platform.